TriangleNCT02715284 · CITED IN SOURCE DOCUMENTS
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE1
- Status at capture
- ACTIVE NOT RECRUITING
- Registry last update
- 2026-08-25
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs) of dostarlimab and will continue until the maximum tolerated dose (MTD) is reached or may be stopped at any dose level up to the highest dose of 20 milligrams per kilograms (mg/kg) based on emerging safety and PK/PDy data. Part 2 will be conducted in two subparts, Part 2A (fixed-dose safety evaluation cohorts) and Part 2B (expansion cohorts). Part 2A of the study will evaluate the safety and tolerability of dostarlimab at fixed doses of 500 mg administered every 3 weeks (Q3W) and 1000 mg administered every 6 weeks (Q6W). Part 2B of the study will examine the safety and clinical activity of dostarlimab in cohorts of participants with specific types of advanced solid tumors.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
No posted result sections were captured. Registered plans do not establish that a treatment works.
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Participant is at least 18 years of age. * Participant has proven recurrent or advanced solid tumor and has disease progression after treatment with available anticancer therapies, or is intolerant to treatment that meets the following requirements for the part of the study they will participate in: A. Part 1: Any histologically or cytologically proven recurrent or advanced solid tumor B. Part 2A: : Any histologically or cytologically proven recurrent or advanced solid tumor C. Part 2B: Histologically of cytologically proven recurrent or advanced solid tumor with measurable lesion(s) per RECIST version 1.1 and meets one of the following disease types: The criteria below should be met for participant participating in: 1) Cohort A1 (dMMR/MSI-H endometrial cancer) and 2) Cohort A2 (MMR-proficient/MSS endometrial cancer) * Participants who have progressed on or after platinum doublet therapy * Participants have received no more than 2 lines of anticancer therapy for recurrent or advanced (\>=Stage IIIB) disease. Prior treatment with hormone therapies is acceptable and does not count towards the number of anticancer therapies noted in the criterion above for this cohort. * All endometrial cancer histologies are allowed except endometrial sarcoma (including carcinosarcoma). * Participants must submit 2 scans demonstrating increase in tumor measurement that meet criteria for PD on or after the latest systemic anticancer therapy based on RECIST Version 1.1 to Central Radiology prior to the first dose of dostarlimab. * Presence of at least 1 measurable lesion on Baseline scan will be confirmed by central radiology review. * Status of tumor MMR/MSI: Participants can be screened based on local MMR/MSI testing results using immunohistochemistry (IHC), polymerase chain reaction (PCR), or next generation sequencing (NGS) performed in a certified local laboratory, but participant eligibility needs to be determined by MMR IHC results. For participant with available local MMR IHC results for the respective cohort(s), tumor samples have to be submitted to a central IHC laboratory and its quality has to be checked and cleared prior to Cycle 1 Day 1 (C1D1). For participants without available local MMR IHC test results (participants with local PCR or NGS test results), central IHC results have to confirm eligibility prior to proceeding with other screening procedures. After the central IHC test is completed, remaining tumor tissue may be tested for further exploratory biomarkers or may be sent to a central NGS laboratory for further testing. 3\) Cohort E - Participants with NSCLC who progressed after at least 1 prior platinum-based systemic chemotherapy regimen for recurrent or advanced disease. * Chemotherapy regimen in the adjuvant or neoadjuvant setting following surgery and/or radiation is acceptable if recurrent or advanced disease develops within 6 months from completion of therapy. * Participants with a known epidermal growth factor receptor (EGFR) mutation must have received a chemotherapy regimen and an EGFR tyrosine kinase inhibitor (TKI) (e.g., erlotinib, gefitinib, afatinib, or experimental) * Participants with a known anaplastic lymphoma kinase (ALK) translocation must have received a chemotherapy regimen and an ALK inhibitor (e.g., crizotinib, ceritinib or experimental) 4) Cohort F - Participants with recurrent or advanced dMMR/MSI-H solid tumors except endometrial cancers and gastrointestinal cancers, who have received prior systemic therapy and who have no alternative treatment options. Prior treatment with hormone therapies alone given for recurrent or advanced disease is acceptable. * Presence of at least 1 measurable lesion by RECIST 1.1 on baseline scan will be confirmed by central radiology review prior to first dose of dostarlimab. Patients with primary central nervous system (CNS) tumor should provide brain MRI at baseline. * Presence of deficient mismatch repair (dMMR) and/or microsatellite instability (MSI-H) in the tumor defined by either: i) deficient DNA mismatch repair (dMMR); MMR status must be assessed by immunohistochemistry (IHC) for MMR protein expression (MLH1, MSH2, MSH6, PMS2) where loss of one or more proteins indicates dMMR; dMMR may be determined either locally or by the central reference lab; OR ii) Microsatellite instability (MSI-H); MSI-H as determined by polymerase chain reaction (PCR) or by tissue NGS; MSI-H may be determined locally 5) Cohort G: Participants must have recurrent high-grade serous, endometrioid, or clear cell ovarian, fallopian tube, or primary peritoneal cancer. * Participants must have presence of at least 1 measurable lesion on Baseline scan that will be confirmed by central radiology review. * Participants must be considered resistant to the last administered platinum therapy, that is, the time from the last administered platinum dose until the initial documented progression (as evidenced by radiographic progression per RECIST version 1.1) must be less than 6 months. * Participants must have completed at least 1 but no more than 3 prior lines of therapy for advanced or metastatic ovarian cancer. Neoadjuvant, adjuvant, and the combination of both will be considered as 1 line of therapy. Treatment with single-agent bevacizumab given as maintenance is not counted as a separate line of therapy. If a therapeutic regimen is modified or changed for a reason other than lack of response or PD (such as allergic reaction, toxicity, or drug availability), this is not counted as a separate line of therapy. The use of single-agent hormonal therapy given for reasons other than PD per RECIST version v1.1 (i.e., hormonal therapy given for increasing Cancer antigen \[CA\]-125 levels) is not counted as a separate line of therapy. * Participants must have been previously treated with platinum-based regimn, taxane agent(s), and bevacizumab (bevacizumab could be used as a single agent or in combination with another agent, in frontline therapy, as maintenance, or for treatment of recurrent disease). • Part 2B: Participants must have archival tumor tissue available that is formalin-fixed and paraffin-embedded (FFPE). * For participants who do not have archival tissue, a new biopsy must be performed to obtain a tissue sample prior to study treatment initiation. For participants without available archival tissue, the biopsy should be taken from the tumor lesions (either primary or metastatic) that have easy accessibility and low biopsy-associated risks and will exclude biopsies of the liver, brain, lung/mediastinum, pancreas, or endoscopic procedures extending beyond the esophagus, stomach or bowel. * For Cohort F an FFPE tissue sample must be submitted to the central laboratory for testing. Specimens containing bone are not acceptable. For patients with available local MMR/MSI-H results, tumor samples have to be submitted to a central laboratory and its quality has to be checked and cleared prior to C1D1 * For Cohort G, participant must provide formalin fixed paraffin embedded (FFPE) tumor tissue block(s) with sufficient tumor content (as confirmed by the Sponsor's designated central laboratory) during screening to enable, for example, measures of homologous recombination pathway defects and PD-L1 status. The use of slides created from paraffin-embedded tissue as opposed to FFPE blocks must be approved by the Sponsor. • Female participants must have a negative serum pregnancy test within 72 hours prior to the date of the first dose of study medication: unless they are of non-child bearing potential.Non child bearing potential is defined as: * \>= 45 years of age and has not had menses for \> 1 year; * Amenorrheic for \< 2 years without a hysterectomy and oophorectomy and have a follicle- stimulating hormone (FSH) value in the postmenopausal range upon pre-study (screening) evaluation. * Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound, magnetic resonance imaging (MRI) or computed tomography (CT) scan. Tubal ligation must be confirmed with medical records of the actual procedure. * Female participants of childbearing potential must agree to use 1 highly effective form of contraception with their partner starting with the screening visit through 150 days after the last dose of study therapy. * Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of \<= 2 for Part 1 and \<= 1 for Part 2. * Participant has an adequate organ function. * Participants with known human immunodeficiency virus (HIV) infection are allowed with following requirements: * Documented evidence of plasma HIV-1 RNA persistently \<50 copies (c)/mL ≤3 months prior to AND at Screening. In the \>3 to 12 months prior to Screening, plasma HIV-1 RNA consistently \<50 c/mL required; if single increases ≥50 c/mL occurred, they cannot have been persistent nor associated with antiretroviral resistance per Investigator's assessment AND * CD4 cell count \>350 cells/mm\^3 over past 12 months and at Screening (and no measurement ≤200 cells/mm3 during that time period) AND * Must be on an uninterrupted combination antiretroviral therapy regimen for at least 3 months prior to Screening, with combination antiretroviral therapy regimen consistent with locally recommended guidelines * Participants with history of Centers for Disease Control and Prevention (CDC) Stage 3 disease (CDC, 2014; also known as acquired immunodeficiency syndrome \[AIDS\]- defining disease) are allowed if AIDS-defining disease has been treated and cured or is stable for ≥3 months prior to study entry. Cutaneous Kaposi's Sarcoma not requiring systemic therapy is allowed. * No history of HIV-associated non-Hodgkin lymphoma ≤5 years prior to study and no history of HIV-associated invasive cervical cancer * No treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening. Exclusion Criteria: * Participant has received prior therapy with an anti- programmed death receptor 1 (anti-PD-1), anti-PD-1- ligand-1 (anti-PD-L1), or anti-PD-1 ligand-2 (anti-PD- L2) agent. * Participant has a known uncontrolled CNS metastasis and/or carcinomatous meningitis. * Participant has a known additional malignancy that progressed or required active treatment within the last 2 years. Exceptions include basal cell carcinoma of the skin, squamous cell cancer (SqCC) of the skin that has undergone potentially curative therapy, or in situ cervical cancer, or other neoplastic condition which has undergone curative therapy and is considered cured by the investigator. * Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active infection requiring systemic therapy. Specific examples include, but are not limited to, active, non-infectious pneumonitis; uncontrolled ventricular arrhythmia; recent (within 90 days) myocardial infarction; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study (including obtaining informed consent). * Participant is pregnant or breastfeeding or expecting to conceive children within the projected duration of the study, starting with the Screening Visit through 150 days after the last dose of study treatment. * Participant has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. * Participant has a documented presence of hepatitis B surface antigen \[HBsAg\] at screening or within 3 months prior to the first dose of study intervention. Participants with a negative HbsAg and positive hepatitis B virus core antibody (HBcAb) result are eligible only if HBV DNA is negative. * Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease- modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Use of inhaled steroids, local injection of steroids, and steroid eye drops are allowed. * Participant has as history of interstitial lung disease. * Participant has not recovered (i.e., to \<= Grade 1 or to Baseline) from radiation- and chemotherapy-induced AEs or received transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including granulocyte-colony stimulating factor \[G-CSF\], granulocyte macrophage colony-stimulating factor \[GM-CSF\] or recombinant erythropoietin) within 3 weeks prior to the first dose of study drug. * Participant has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of study drug. * Participant has received prior anticancer therapy (chemotherapy, targeted therapies, radiotherapy, or immunotherapy) within 21 days prior to study Day 1 * Participant has not recovered adequately (\<= Grade 1) from AEs and/or complications from any major surgery prior to starting therapy. * Participant has received a live vaccine within 14 days of planned start of study therapy. * Participant has a known hypersensitivity to dostarlimab components or excipients. * For Cohort G, participants will not be eligible if they meet the following criteria: * Participants who experienced disease progression within 3 months (as evidenced by radiographic progression per RECIST) of first-line platinum therapy. * Participants with known deleterious or suspicious deleterious mutation in BRCA1 or BRCA2 genes (local testing permitted). * Participants has received prior therapy with a poly(adenosine diphosphate-ribose) polymerase (PARP)-1/PARP-2 inhibitor. * Participant has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, might interfere with the participant's participation for the full duration of the study treatment, or is not in the best interest of the participant to participate. * Participant is immunocompromised. Participants with splenectomy are allowed.
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Part 1 will evaluate dostarlimab at ascending weight-based doses 1 mg/kg, 3 mg/kg and 10 mg/kg. Higher dose levels 15 mg/kg and/or 20 mg/kg may also be explored. Dostarlimab will be administered intravenously (IV) on Day 1 and Day 15 of each cycle; cycle length is 28 days. Cohorts will be enrolled sequentially and will initially follow a 3+3 design.
- intervention Names
- Biological: Dostarlimab
- label
- Part 1: Participants receiving dostarlimab
- type
- EXPERIMENTAL
- description
- In Part 2A, participants will receive fixed dose of 500 mg administered Q3W or 1000 mg administered Q6W dose on Day 1 of each cycle. Cycle duration for Q3W dosing is 21 days and Q6W dosing is 42 days. Cohorts will enroll participants with advanced solid tumor using a modified 6+6 design and will follow a 6+6 design.
- intervention Names
- Biological: Dostarlimab
- label
- Part 2A: Participants receiving dostarlimab
- type
- EXPERIMENTAL
- description
- Part 2B: Cohort A1 will include participants with mismatch repair deficient microsatellite instability high (dMMR/MSI-H) endometrial cancer who have progressed on or after platinum doublet therapy. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles. Participants have received no more than 2 lines of anti-cancer therapy for recurrent or advanced (Stage \>= IIIB) disease.
- intervention Names
- Biological: Dostarlimab
- label
- Part 2B: Cohort A1 dMMR/MSI-H endometrial cancer
- type
- EXPERIMENTAL
- description
- Part 2B: Cohort A2 will include participants with MMR-proficient/MSS endometrial cancer who have progressed on or after platinum doublet therapy. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles. Participants have received no more than 2 lines of anti-cancer therapy for recurrent or advanced (Stage \>=IIIB) disease.
- intervention Names
- Biological: Dostarlimab
- label
- Part 2B: Cohort A2 MMR-proficient/MSS endometrial cancer
- type
- EXPERIMENTAL
- description
- Part 2B: Cohort E NSCLC will include participants with non-small cell lung cancer (NSCLC) who progressed after at least 1 prior platinum-based systemic chemotherapy regimen for recurrent or advanced disease. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles.
- intervention Names
- Biological: Dostarlimab
- label
- Part 2B: Cohort E NSCLC
- type
- EXPERIMENTAL
- description
- Participants with recurrent or advanced dMMR/MSI-H solid tumors except endometrial cancers, and gastrointestinal cancers, who have received prior systemic therapy and, who have no alternative treatment options. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles.
- intervention Names
- Biological: Dostarlimab
- label
- Part 2B: Cohort F non-endometrial dMMR/MSI-H or POLE-Mut cancers
- type
- EXPERIMENTAL
- description
- Participants with advanced, relapsed, high-grade serous, endometrioid, or clear cell ovarian, fallopian tube, or primary peritoneal cancer without known breast cancer susceptibility gene (BRCA) mutation who have platinum-resistant disease receiving dostarlimab and who have also been previously treated with bevacizumab. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles.
- intervention Names
- Biological: Dostarlimab
- label
- Part 2B: Cohort G PROC without known BRCA
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Part 1: Participants receiving dostarlimab
- Part 2A: Participants receiving dostarlimab
- Part 2B: Cohort A1 dMMR/MSI-H endometrial cancer
- Part 2B: Cohort A2 MMR-proficient/MSS endometrial cancer
- Part 2B: Cohort E NSCLC
- Part 2B: Cohort F non-endometrial dMMR/MSI-H or POLE-Mut cancers
- Part 2B: Cohort G PROC without known BRCA
- description
- Dostarlimab (160 mg, 20 mg/mL; or 500 mg, 50 mg/mL) is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2). Dostarlimab will be administered via a 30 minute IV infusion on Day 1 and Day 15 of each cycle in Part 1. For additional patients enrolled specifically to better characterize the PK/PDy profile in Part 1, dostarlimab administration during Cycle 1 will only occur on Day 1 with the second dose administered on Cycle 2/Day 1 and Q2W thereafter. For Part 2A and 2B, dostarlimab will be administered on Day 1 of each treatment cycle. Cycle duration for Q3W dosing is 21 days and Q6W dosing is 42 days.
- name
- Dostarlimab
- type
- BIOLOGICAL
Study design
- allocation
- NON_RANDOMIZED
- intervention Model
- SEQUENTIAL
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 729
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- An adverse event (AE) is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including clinically significant abnormal laboratory findings), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the product. TEAEs defined as any AE either reported for the first time or worsening of a pre-existing event after first dose of study treatment.
- measure
- Part 1: Number of participants with treatment emergent AEs (TEAEs)
- time Frame
- Up to 2 years
- description
- Participants with immune related AEs of interest will be assessed.
- measure
- Part 1: Number of participants with immune mediated AEs of interest
- time Frame
- Up to 2 years
- description
- Blood samples will be collected to assess the following hematology parameters: hemoglobin, Mean corpuscular (MCV), white blood cell count (WBC count), platelets, mean platelet volume, differential WBC count and coagulation factors including International normalized ratio (INR), activated partial thromboplastin time (aPTT) and prothrombin time (PT).
- measure
- Part 1: Number of participants with abnormal hematology parameters
- time Frame
- Up to 2 years
- description
- Blood samples will be collected to assess the following chemistry parameters: sodium, potassium, calcium, magnesium, creatinine, bilirubin, alkaline phosphatase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and albumin.
- measure
- Part 1: Number of participants with abnormal clinical chemistry parameters
- time Frame
- Up to 2 years
- description
- Number of participants will be assessed.
- measure
- Part 1, Part 2A, and Part 2B: Number of participants with a change from baseline in urinalysis parameters
- time Frame
- Up to 2 years
- description
- Number of participants will be assessed.
- measure
- Part 1, Part 2A, and Part 2B: Number of participants with a change from baseline in vital signs
- time Frame
- Up to 2 years
- description
- Participants will be supine or in a semi-recumbent position and rested for approximately 2 minutes before ECGs are recorded.
- measure
- Part 1: Number of participants with abnormal electrocardiogram (ECG) parameters
- time Frame
- Up to 2 years
- description
- Concomitant medications will be recorded.
- measure
- Part 1: Number of participants receiving concomitant medications
- time Frame
- Up to 2 years
- description
- An AE is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including clinically significant abnormal laboratory findings), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the product. TEAEs defined as any AE either reported for the first dose of study treatment.
- measure
- Part 2A: Number of participants with TEAEs
- time Frame
- Up to 2 years
- description
- Participants with immune related AEs of interest will be assessed.
- measure
- Part 2A: Number of participants with immune mediated AEs of interest
- time Frame
- Up to 2 years
- description
- Blood samples will be collected to assess the following hematology parameters: hemoglobin, MCV, white WBC count, platelets, mean platelet volume, differential WBC count and coagulation factors including INR, aPTT and PT.
- measure
- Part 2A: Number of participants with abnormal hematology parameters
- time Frame
- Up to 2 years
- description
- Blood samples will be collected to assess the following chemistry parameters: sodium, potassium, calcium, magnesium, creatinine, bilirubin, AST, ALT, and albumin.
- measure
- Part 2A: Number of participants with abnormal clinical chemistry parameters
- time Frame
- Up to 2 years
- secondary Outcomes
- description
- Immune-related objective response rate will be evaluated based on investigator's assessment using irRECIST.
- measure
- Part 1: Immune-related objective response rate (irORR) by irRECIST
- time Frame
- Up to 2 years
- description
- ORR is defined as the proportion of participants achieving CR or PR as evaluated by independent blinded central review using RECIST version 1.1.
- measure
- Part 2B: Cohort A1 ORR by independent blinded central review using RECIST version 1.1
- time Frame
- Up to 2 years
- description
- ORR is defined as the proportion of participants achieving CR or PR as evaluated by independent blinded central review using RECIST version 1.1.
- measure
- Part 2B: Cohort F ORR by independent blinded central review using RECIST version 1.1
- time Frame
- Up to 2 years
- description
- Immune related objective response rate will be evaluated based on investigator's assessment using irRECIST.
- measure
- Part 2B: Cohort A1 Immune-related objective response rate (irORR) by irRECIST
- time Frame
- Up to 2 years
- description
- Immune related objective response rate will be evaluated based on investigator's assessment using irRECIST.
- measure
- Part 2B: Cohort A2 irORR by irRECIST
- time Frame
- Up to 2 years
- description
- Immune related objective response rate will be evaluated based on investigator's assessment using irRECIST.
- measure
- Part 2B: Cohort F irORR by irRECIST
- time Frame
- Up to 2 years
- description
- Immune related objective response rate will be evaluated based on investigator's assessment using irRECIST.
- measure
- Part 2B: Cohort G irORR by irRECIST
- time Frame
- Up to 2 years
- description
- DOR is defined as the time from first documentation of CR or PR by RECIST version 1.1 until the time of first documentation of progressive disease (PD) evaluated using RECIST version 1.1 based on independent blinded central review, or death due to any cause.
- measure
- Part 2B: Cohort A1 Duration of response (DOR) based on independent blinded central review using RECIST version 1.1
- time Frame
- Up to 2 years
- description
- DOR is defined as the time from first documentation of CR or PR by RECIST version 1.1 until the time of first documentation of PD evaluated using RECIST version 1.1 based on independent blinded central review, or death due to any cause.
- measure
- Part 2B: Cohort F DOR based on independent blinded central review using RECIST version 1.1
- time Frame
- Up to 2 years
- description
- DOR is defined as the time from first documentation of CR or PR by RECIST version 1.1 until the time of first documentation of PD evaluated using RECIST version 1.1 based on independent blinded central review, or death due to any cause.
- measure
- Part 2B: Cohort G DOR based on independent blinded central review using RECIST version 1.1
- time Frame
- Up to 2 years
- description
- Disease control rate is the proportion of participants achieving CR, PR, or SD per RECIST v1.1 based on independent blinded central review.
- measure
- Part 2B: Cohort A1 Disease control rate
- time Frame
- Up to 2 years
- description
- Disease control rate is the proportion of participants achieving CR, PR, or SD per RECIST v1.1 based on independent blinded central review.
- measure
- Part 2B: Cohort A2 Disease control rate
- time Frame
- Up to 2 years
Full study description
- brief Summary
- This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs) of dostarlimab and will continue until the maximum tolerated dose (MTD) is reached or may be stopped at any dose level up to the highest dose of 20 milligrams per kilograms (mg/kg) based on emerging safety and PK/PDy data. Part 2 will be conducted in two subparts, Part 2A (fixed-dose safety evaluation cohorts) and Part 2B (expansion cohorts). Part 2A of the study will evaluate the safety and tolerability of dostarlimab at fixed doses of 500 mg administered every 3 weeks (Q3W) and 1000 mg administered every 6 weeks (Q6W). Part 2B of the study will examine the safety and clinical activity of dostarlimab in cohorts of participants with specific types of advanced solid tumors.
Source references
- references
- citation
- Patnaik A, Weiss GJ, Rasco DW, Blaydorn L, Mirabella A, Beeram M, Guo W, Lu S, Danaee H, McEachern K, Im E, Sachdev JC. Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial. Cancer Chemother Pharmacol. 2022 Jan;89(1):93-103. doi: 10.1007/s00280-021-04358-3. Epub 2021 Nov 8.
- pmid
- 34750637
- type
- BACKGROUND
- citation
- Zhang XT, Chen H, Shao W, Zhongping JL, Melham M, Lu S.A Competitive Ligand Binding Assay to Measure Antidrug Antibodies Against Dostarlimab (TSR-042).2021; DOI: 10.1186/s41120-021-00039-w
- type
- BACKGROUND
- citation
- Patterson M, Beausang LA, Rup B, Bowsher R, Krug K, Gunn G, Melham M, Lu S.A Bridging Assay for Detection and Characterization of Anti-Drug Antibodies to Dostarlimab, a New Anti-PD-1 Therapeutic Monoclonal Antibody .2021;7(11) DOI: DOI 10.1186/s41120-021-00045-y
- type
- BACKGROUND
- citation
- Kumar S, Ghosh S, Sharma G, Wang Z, Kehry MR, Marino MH, Neben TY, Lu S, Luo S, Roberts S, Ramaswamy S, Danaee H, Jenkins D. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models. MAbs. 2021 Jan-Dec;13(1):1954136. doi: 10.1080/19420862.2021.1954136.
- pmid
- 34313545
- type
- BACKGROUND
- citation
- Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, Sabatier R, O'Malley DM, Samouelian V, Boni V, Duska L, Ghamande S, Ghatage P, Kristeleit R, Leath C III, Guo W, Im E, Zildjian S, Han X, Duan T, Veneris J, Pothuri B. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer. 2022 Jan;10(1):e003777. doi: 10.1136/jitc-2021-003777.
- pmid
- 35064011
- type
- BACKGROUND
- citation
- Kristeleit R, Mathews C, Redondo A, Boklage S, Hanlon J, Im E, Brown J. Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab. Int J Gynecol Cancer. 2022 Oct 3;32(10):1250-1257. doi: 10.1136/ijgc-2022-003492.
- pmid
- 35973737
- type
- BACKGROUND
- citation
- Kuchimanchi M, Dabrowski C, Lu S, Melhem M. Dostarlimab, an anti-programmed death-1 monoclonal antibody, does not cause QT prolongation in patients with solid tumours: A concentration-QT analysis. Br J Clin Pharmacol. 2023 Jul;89(7):2272-2282. doi: 10.1111/bcp.15700. Epub 2023 Mar 20.
- pmid
- 36823349
- type
- BACKGROUND
- citation
- Andre T, Berton D, Curigliano G, Sabatier R, Tinker AV, Oaknin A, Ellard S, de Braud F, Arkenau HT, Trigo J, Gravina A, Kristeleit R, Moreno V, Abdeddaim C, Vano YA, Samouelian V, Miller R, Boni V, Torres AA, Gilbert L, Brown J, Dewal N, Dabrowski C, Antony G, Zografos E, Veneris J, Banerjee S. Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial. JAMA Netw Open. 2023 Nov 1;6(11):e2341165. doi: 10.1001/jamanetworkopen.2023.41165.
- pmid
- 37917058
- type
- DERIVED
- citation
- Rodrigues M, Eberst L, Follana P, Gauthier L, Jacquemin V, Tessier C, El Mouaddin N, Boudier P, Fiteni F, Angeli E, Roche S, Delanoy N, Sabatier R, Flippot R, de la Motte Rouge T. Real-world dostarlimab use in advanced/recurrent endometrial cancer in France. Bull Cancer. 2023 Oct;110(10):1041-1050. doi: 10.1016/j.bulcan.2023.06.009. Epub 2023 Aug 31.
- pmid
- 37659907
- type
- DERIVED
- citation
- Oaknin A, Pothuri B, Gilbert L, Sabatier R, Brown J, Ghamande S, Mathews C, O'Malley DM, Kristeleit R, Boni V, Gravina A, Banerjee S, Miller R, Pikiel J, Mirza MR, Dewal N, Antony G, Dong Y, Zografos E, Veneris J, Tinker AV. Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study. Clin Cancer Res. 2023 Nov 14;29(22):4564-4574. doi: 10.1158/1078-0432.CCR-22-3915.
- pmid
- 37363992
- type
- DERIVED
- citation
- Moreno V, Roda D, Pikiel J, Trigo J, Bosch-Barrera J, Drew Y, Kristeleit R, Hiret S, Bajor DL, Cruz P, Beck JT, Ghosh S, Dabrowski C, Antony G, Duan T, Veneris J, Zografos E, Subramanian J. Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial. Clin Lung Cancer. 2022 Nov;23(7):e415-e427. doi: 10.1016/j.cllc.2022.05.013. Epub 2022 May 23.
- pmid
- 35729005
- type
- DERIVED
- citation
- Oaknin A, Tinker AV, Gilbert L, Samouelian V, Mathews C, Brown J, Barretina-Ginesta MP, Moreno V, Gravina A, Abdeddaim C, Banerjee S, Guo W, Danaee H, Im E, Sabatier R. Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer. Future Oncol. 2021 Oct 1;17(29):3781-3785. doi: 10.2217/fon-2021-0598. Epub 2021 Aug 24.
- pmid
- 34427115
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-28a97c8bbbc0306c15da
- requested nct id
- NCT02715284
- primary nct id
- NCT02715284
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- 68c1706258e98d38c9ed48fd0c71432d06d320b05c8885ceb5fa728eadea7590
- payload sha256
- ef8b1142440cab3ab47d18427176bfd9b7f8c9cc2ee84aed3d5762457e31dd78
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-28a97c8bbbc0306c15da
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT02715284
- occurrences
- context exact
- options. This indication is not approved in the pediatric population. </p> <p id="_215" tabindex="-1"><strong>Evidence.</strong> <a href="/clinicaltrials/NCT02715284">GARNET</a> (NCT02715284) was a nonrandomized, multicenter, open-label, multicohort trial that evaluated the efficacy of dostarlimab.[<a href="#cit/section_2.1
- end
- 25779
- exact text
- NCT02715284
- start
- 25768
- context exact
- is not approved in the pediatric population. </p> <p id="_215" tabindex="-1"><strong>Evidence.</strong> <a href="/clinicaltrials/NCT02715284">GARNET</a> (NCT02715284) was a nonrandomized, multicenter, open-label, multicohort trial that evaluated the efficacy of dostarlimab.[<a href="#cit/section_2.10">10</a>] The expansion
- end
- 25804
- exact text
- NCT02715284
- start
- 25793
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/673b6b58fe51113964.html
- source file sha256
- 68c1706258e98d38c9ed48fd0c71432d06d320b05c8885ceb5fa728eadea7590
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:21:27.710469+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- dd1d1d1ad91100ad4c1f7e9f55ba1a72466b1757ab229115c118a2a0940b3724
- source title
- Agnostic Cancer Therapies (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: February 12, 2025
- datetime
- 2025-02-12T12:00:00Z
- display
- February 12, 2025
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-e14ccb0574ee4e2cc3ca
- requested nct id
- NCT02715284
- primary nct id
- NCT02715284
- source kind
- fda_spl_label
- source record id
- da2ad681-d178-42c9-aa55-47c619cc7cb1
- source file sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- payload sha256
- a99bbb1ae08b0e78aa372b86f7f553aed8c5cf0bb819a4121def5a31060e52be
- payload
- application numbers
- BLA761174
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-e14ccb0574ee4e2cc3ca
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT02715284
- occurrences
- context exact
- a Single Agent for the Treatment of dMMR Recurrent or Advanced Endometrial Cancer The efficacy of JEMPERLI as a single agent was evaluated in the GARNET trial (NCT02715284), a multicenter, multicohort, open-label trial conducted in patients with advanced solid tumors. The efficacy population consisted of a cohort of 141 patients
- end
- 6289
- exact text
- NCT02715284
- start
- 6278
- context exact
- igure 1 Figure 2 Figure 3 14.2 Mismatch Repair Deficient Recurrent or Advanced Solid Tumors The efficacy of JEMPERLI as a single agent was evaluated in GARNET (NCT02715284), a non‑randomized, multicenter, open-label, multicohort trial. The efficacy population consisted of a cohort of 209 patients with dMMR recurrent or advanced s
- end
- 8853
- exact text
- NCT02715284
- start
- 8842
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00700.json
- source file sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source json pointer
- /results/15/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- da2ad681-d178-42c9-aa55-47c619cc7cb1
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- f017330de659c776d7495a2baeb2b971f2009117d3ef9de1dbd8add844c5a828
- spl effective time
- 20250902
- spl set id
- 095eab9f-545a-4f12-bfb7-19477fb901a5
Preserved source evidence · Independent clinical review pending · Not medical advice